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Body dysmorphic disorder (BDD) is a psychosomatic di-
sease associated with reduced quality of life and suicidal 
ideations. Increasing attention to beauty and the deve-
lopment of beauty industries lead to the hypothesis that 
BDD is increasing. The aim of this study was to test this 
hypothesis in two representative samples of Germans, 
assessed in 2002 and 2013. In 2002, n = 2,066 and in 2013, 
n = 2,508  Germans  were  asked  to  fill  in  the  Dysmorp-
hic Concern Questionnaire (DCQ), which assesses dys-
morphic concerns. Subclinical and clinical dysmorphic 
concerns increased from 2002 to 2013 (subclinical from 
0.5% to 2.6%, OR = 5.16 (CI95% = 2.64; 10.06); clinical 
from 0.5% to 1.0%, OR = 2.20 (CI95% = 1.03; 4.73). Wo-
men reported more dysmorphic concerns than men, with 
rates of 0.7% subclinical and 0.8 clinical BDD in women 
and 0.3% subclinical and 0.1% clinical BDD in men in 
2002. In 2013, 2.8% subclinical and 1.2% clinical BDD 
were found in women and 2.4% subclinical and 0.8% 
clinical BDD in men. Further studies should assess pre-
dictors for developing a BDD and evaluate factors deter-
mining the efficacy of disease-specific psycho therapeutic 
and psychotropic drug treatments. Key words: cognititive 
behavior therapy; psychodynamic psychotherapy; body 
scheme; body image; dermatology.
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The psychiatrist Morselli described body dysmorphic dis-
order (BDD) and introduced the term Dysmorpho phobia 
as early as 1886 (1). Subsequently, other psychiatrists 
also described young women who feared, because of 
their imagined ugliness, they would not find a lover (2). 
There are now increasingly frequent publications on this 
phenomenon (3–6). In 1987, the clinical picture of BDD 
was included in the DSM-IV as an official disorder diag-
nosis in the USA (7). Meanwhile, BDD is accepted as an 
independent syndrome in the DSM-IV-R and also in the 
ICD-10 (8). In the ICD-10, BDD is assigned to somato-
form disorders (9). In the DSM-5, it is newly included in 
the compulsive disorders category (10). Delineation from 
compulsive disorders, hypochondriacal disorders as well 
as dysmorphic disorders in anorexia nervosa or bulimia 
must be differential-diagnostically determined (11).
BDD is a chronic emotional disorder, in which the af-
flicted cannot stop brooding over a minimal or imagined 
flaw (12–15). They experience their appearance as so 
disfigured that they are ashamed and prevent others from 
seeing them. These patients spend several hours a day 
checking themselves and their appearance in the mirror 
(mirror-checking), or they avoid mirrors and mirroring 
surfaces (12). Moreover, the patients use cosmetic pro-
ducts to cover up the imagined flaw, or they excessively 
manipulate their skin (12, 13, 15–17). However, they are 
rarely satisfied with the result or in harmony with their 
self-image. This emotional disorder, projected to the 
skin surface, affects especially the face, nose, ears and 
secondary sex characteristics (15). Objective observers 
usually cannot see the flaw (DSM 5 criterion A). People 
with BDD show a need to constantly assure themselves 
that everything looks “as it should”. Often, however, they 
avoid social contacts, public places, work and school. 
Many only leave the house at night (12, 17). 
The BDD correlates with social withdrawal to an 
extent greatly exceeding normal shyness and may reach 
a clinical expression of social phobia (14, 18). The 
withdrawal can result in that the afflicted person no 
longer engage in or make new interpersonal contacts, 
are socially excluded, and become unable to work (19). 
Other comorbidities are eating disorders (20), anxiety 
and affective disorders (15, 21, 22). In this context, there 
is usually weight gain with subsequent diets. Suicidal 
reactions occur in about 15% of the cases in this vicious 
circle (23). The desire and implementation of cosmetic-
dermatological and plastic-surgical interventions bring 
the corresponding risk of subsequent adverse events or 
lead to addiction to surgery (24, 25).
Various instruments are recommended for the diag-
nostic recording of BDD, some of which are used for 
clinical diagnostics or as screening questionnaires. The-
re are two forms of interviews suitable to identify BDD. 
The structured Interview Diagnostic Module for BDD 
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by Philipps et al. (17) (BDDDM) is recommended for 
clinical use. It is based on the DSM-4, and DSM-5 crite-
ria, respectively and was also used in the representative 
studies by Rief et al. (26) and Buhlmann et al. (27). 
Moreover, there are semi-structured interviews, the so-
called Yale-Brown Obsessive-Compulsive Scale (BDD-
YBOCS) (28). The severity of the emotional symptoms 
and information for behaviour analysis can be obtained 
using these procedures. There are also questionnaires to 
record BDD: The DCQ was validated in Germany by 
Stangier et al. (29) and enables distinguishing between 
patients with a subclinical and clinical degree of BDD. 
It contains only 7 items and thus can be easily used as 
a screening instrument (see the Methods section for a 
precise description). In addition to the DCQ, two other 
questionnaires are used in the German-speaking region. 
The KDS-F (Körperdysmorpher Störungs-Fragebogen/
Body Dysmorphic Disorder Questionnaire) with 43 
items that can be categorized into 3 main scales and the 
KDS-K (short form of the KDS-F) (30). Buhlmann et 
al. (31) developed a questionnaire on BDD according to 
the criteria of the DSM-4 and validated it in 45 patients 
with BDD and control persons. 
EPIDEMIOLOGY OF BODY DYSMORPHIC 
DISORDER
Some studies investigated the point-prevalence of BDD in 
the general population. In Germany, Rief et al. (26) found 
a frequency of 1.7%, whereas Stangier (32) reported a 
point-prevalence of 0.9%. Buhlmann et al. (27) found a 
point-prevalence of 1.8%. The differing data could be re-
lated to the different recording instruments that were used. 
Faravelli et al. (33) studied the prevalence exclusively in 
Florence, identifying 0.7% of the population, and Otto et 
al. (34) studied only women in the US in 7 US-American 
cities where data were recorded in a case-control study. 
Here, a prevalence of 0.7% was determined using structu-
red interviews. In a North-American sample, Koran et al. 
(35) found a prevalence of 2.4%, using computer-assisted 
interviews meeting the criteria of the DSM-IV. Thus, BDD 
appears to be more frequent than, for example, hidrade-
nitis suppurativa, which has a presumed prevalence of 
approximatively 1% of the population (36). 
Considerably higher prevalences were found in 
specific settings. For example, it could be shown that 
in dermatological outpatient offices between 6.4 and 
11.9% (29, 37–42) of the patients were affected, and 
also 5.7–7.0% of the plastic-surgery patients (43). 
In cosmetic-dermatological settings, BDD occurred 
in 6.3–15.2% of the patients (37, 38, 42, 44, 45). In 
psychiatric populations, between 0.5 and 10% of the 
patients are affected, (46–49), whereas a prevalence of 
about 4% has been reported in students (50, 51). 
Table I presents an overview of studies to date on the 
prevalence of BDD in various settings. 
So far, there are no studies on the prevalence of BDD 
which have answered the question of the extent to which 
Table I. Prevalences of body dysmorphic disorder (BDD) in various settings 
Setting Prevalence Instruments n Authors (ref)
General 
population
1.7% (Germany)
0.9% (Germany)
DSM-IV-criteria
Dysmorphic Concern Questionnaire
2,552 national survey Rief et al. 2006 (26)
Stangier 2007 (32)
0.7% (only Florence) Personal interview by general practitioner 2,066 national survey Faravelli et al. 1997 (33)
2.4% (USA- 1 City) Computer-assisted structured interviews 673 interviews Koran et al. 2008 (35)
1.8 % (Germany) DSM-4 criteria 2,048 telephone interview Buhlmann et al. 2010 (27)
2.1% (only women) BDD Questionnaire (BDDQ) 2,891 Swedish women Brohede et al. 2014 (59)
0.8% (Germany) BDD criteria DSM-V 2,129 national survey Schieber et al. 2015 (5)
Dermato-
logical 
offices
11.9%
8.7%
9.0%
7.9%
6.6%
6.7%
4.2%
Self-report questionnaire
Dysmorphic Concern Questionnaire
Dysmorphic Concern Questionnaire
Dysmorphic Concern Questionnaire
Dysmorphic Concern Questionnaire
BDD Questionnaire + DSM-IV Interview
Self-report BDD screening
268 dermatological patients
126 dermatological patients
156 patients
61
300
200
Phillips et al. 2000 (39)
Stangier et al. 2003 (41)
Stangier et al. 2003 (29)
Ritter et al. 2013 (40)
Wiedersich 2010 (42)
Conrado et al. 2010 (37)
Dogruk Kacar et al. 2014 (38)
Plastic 
surgery
7.0%
5.7%
2 body image measures
Dysmorphic Concern Questionnaire
100 women
36
Sarwer et al. 1998 (63)
Wiedersich 2010 (42)
Cosmetic 
dermato-
logy
6.3%
15.2%
11.5%
14.0%
8.6%
13.1%
BDD-YBOCS + SCID-I
Brief self-report questionnaire
Dysmorphic Concern Questionnaire
BDD Questionnaire + DSM-IV Interview
Self-report BDD screening
BDD Structured Clinical Interview for 
DSM-IV (BDD SCID)
487
46
54
300
200
234
Altamura et al. 2001 (44)
Dufresne et al. 2001 (45)
Wiedersich 2010 (42)
Conrado et al. 2010 (37)
Dogruk Kacar et al. 2014 (38)
Dey et al. 2015 (64)
Patients 
with 
mental 
disorders
10%
1.8% (Germany) 
10%
1.9%
Psychiatric interview
Self report DSM-IV criteria
BDD module DSM-IV
BDD module DSM-IV
255 psychiatric patients
318 depressed and 658 non-depressed
350 psychiatric patients
155 German psychiatric patients
Brawman-Mintzer et al. 1995 (46)
Otto et al. 2001 (34)
Nierenberg et al. 2002 (48)
Kollei et al. 2011 (47)
Student 
population
5.3% 
4.9%
DSM-IVmodule criteria
Cross-sectional study
133 German students
1,041 US students
Bohne et al. 2002 (50)
Boroughs et al. 2010 (65)
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the disorder has increased in frequency over the past 
years. Attractiveness seems increasingly important for 
professional and social integration. This makes it plau-
sible that rejection in everyday life is more frequently 
attributed to personal appearance and physical flaws 
and more intensively perceived or assumed. For this 
reason, the present study is intended to check whether 
dysmorphic concerns and the tendency to BDD have 
increased. The DCQ, as a validated instrument, was 
used to determine the prevalence of BDD in two large 
representative samples in Germany. 
METHODS
Representative sample 
As part of a survey conducted by a professional institute 
(USUMA GmbH Berlin), persons in all parts of Germany were 
visited at home in the period of November to December 2002, 
and February to April 2013, respectively. The DCQ was used in 
this survey with a series of other psychosocial questionnaires. 
The data from the other questionnaires are being processed 
by the pertinent authors and are not part of the present study. 
To obtain a representative sample of the population, a customary 
procedure in market research for sampling (random route) was 
used. First, the households to be questioned were selected. The 
target household in a certain region was selected by a randomiza-
tion procedure using a multistep process (52). Within the target 
households, the person to be questioned was then determined using 
another randomized selection procedure (Schwedenschlüssel or 
Kish-Selection-Grid (53). In this procedure, each member of a 
household had the same chance of being selected for questioning. 
Target persons who were not reached on first contact had to be 
visited two more times at various times a day before they could be 
assigned to a drop-out reason. Differentiation was made between 
quality-neutral drop-outs, for example untenanted dwelling, and 
systematic drop-outs, when the person was not reached despite 
triple attempts. For the present study in 2013, 3,855 households 
were visited by trained interviewers (evaluable data from 2,508), 
while in 2002, 3,194 households were visited (evaluable data from 
2,066). The selected sample corresponds to information from the 
Federal Bureau of Statistics (Statistisches Bundesamt (54, 55)). 
Table II compares the samples of the years 2002 and 2013, in 
which the DCQ data were evaluable.
Questionnaires
Dysmorphic Concern Questionnaire (DCQ). The DCQ in the Ger-
man validation (29) was used in order to screen for BDD. The DCQ 
was developed from the General Health Questionnaire according 
to Goldberg (56) by Oosthuizen et al. (57). The DCQ consists of 
7 items, which have to be rated on a 4–point scale from 0–3 (not 
at all, like most people, more than other people, much more than 
other people) (Example item: “been told by others/doctor that you 
are normal in spite of your strongly believing that something is 
wrong with your appearance or bodily functioning”). 
Stangier et al. (29) validated the DCQ in an unselected sam-
ple of 156 dermatological patients, additionally in 22 patients 
with clinically-proven BDD, 22 patients with disfiguring skin 
diseases and 21 patients with non-disfiguring skin diseases. A 
Cronbach´s α of 0.85 was calculated for the German version 
of the DCQ. The one extracted factor in the factor analysis 
explained 53.8% of the variance.
The convergent validity was determined by correlations with 
depression (r = 0.33) and compulsive disorders (r = 0.57–0.74). 
Moreover, a discriminative validity could be examined across the 
various samples. A cut-off value of  ≥ 14 represented the best com-
promise between sensitivity and specificity. Seventy-two percent 
of the BDD patients could be correctly assigned to the diagnosis 
of BDD using this value. DCQ values between ≥ 11 points and 
< 14 points indicate a possible BDD and are termed a subclinical 
form. These two cut-off values were also used in this study to dif-
ferentiate between a subclinical or clinical form of BDD. 
Statistical data analysis
Statistical analyses were performed using IBM SPSS Statistic 
(SPSS Version 22 for Windows 2013 (58)). χ2-tests were per-
formed to compare the frequency distributions. Afterwards, 
changes in the prevalence from 2002 compared to 2013 were 
determined by means of Odds ratios (OR; with confidence 
interval 95%). Moreover, the OR were determined for the com-
parison of degrees of the test variables (men/women; without 
university entrance diploma/ with university entrance diploma; 
with partner/without partner). Analyses of variance were used 
to compare differences between the two sample groups. Main 
differences were calculated at α = 0.05, with η2 as effect size. 
RESULTS
A first evaluation was made using descriptive statistics 
regarding the point prevalence of BDD in the two repre-
sentative samples. For this, the two cut-off values of the 
DCQ of ≥ 11–< 14 for subclinical disfiguration and ≥ 14 
as clinically-relevant disfiguration in the sense of a BDD 
were used. Comparison of the data from 2002 and 2013 re-
vealed an increase in the presence of dysmorphic concerns. 
While in 2002 0.5% of the subjects reported sub-
clinical symptoms, 2.6% of the subjects in 2013 did 
(OR = 5.16; CI95% = 2.64; 10.06). An increase from 
Table II. Characteristics of the representative samples in 2002 
and 2013*
2002 
n = 2,066 
% (n)
2013 
n = 2,508 
% (n)
Evaluable Dysmorphic Concern 
Questionnaire-Data 
93.5 (1,934) 99.8 (2,504) 
Women 53.4 (1,032) 53.2 (1,331)
Highest educational degree (MD=10)
School education without university 
entrance diploma
86.7 (1,677) 81.8 (2,040)
University entrance diploma or higher 13.3 (257) 18.2 (454)
Employment
Without job   8.5 (165)   5.7 (142)
Working 43.5 (842) 52.1 (1,304)
Not working 47.9 (927) 42.3 (1,058)
Partnership
Living with partner 55.6 (1,076) 52.5 (1,314)
Without partner 44.4 (858) 47.5 (1,190)
Age
< 24 years 12.0 (232) 10.2 (256)
25–34 years 13.1 (253) 14.3 (359)
35–44 years 17.6 (340) 15.2 (381)
45–54 years 16.3 (315) 17.8 (445)
55–64 years 17.8 (345) 18.1 (453)
65–74 years 14.9 (289) 15.2 (381)
> 75 years   8.3 (160)   9.1 (229)
*Self-reported by participants of the study.
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0.5% to 1% of those questioned could also be observed 
with respect to the frequency of clinically-relevant 
symptoms (OR = 2.20; CI95% = 1.03; 4.73). The fre-
quency distribution of no, subclinical and clinical BDD 
differs significantly between the years 2002 and 2013 
(χ2 (2) = 32.71; p < 0.001).
The increase in prevalence of BDD is seen both in 
the subclinical and clinical form of BDD according to 
DCQ diagnostics in the entire sample. Both women and 
men more often reported subclinical symptoms in 2013 
than in 2002 (women: OR = 4.21 CI95% = 1.87; 9.47; 
men: OR = 7.38; CI95% = 2.24; 24.35).
The subgroup without university entrance diploma 
also showed a higher prevalence of subclinical BDD 
in 2013 (OR = 9.49; CI95% = 3.79; 23.76), as did the 
subgroups with (OR = 5.38; CI95% = 2.09; 13.86) and 
without partner (OR = 4.89; CI95% = 1.90; 12.57).
Since the numbers regarding the prevalence in the indi-
vidual age groups were small, no OR were determined in 
that case. Overall, however, it was observed that a more 
marked increase in prevalence is seen in the younger age 
groups (up to 54 years) than in the older groups. 
With one exception, all comparisons between the 
degrees of the variables (men vs. women; without 
university entrance diploma/ with university entrance 
diploma; with partner/without partner) showed no 
noteworthy ORs. No statements can be made concer-
ning an increase from 2002 to 2013 with respect to age 
because of the small sample size. In 2013, dysmorphic 
concerns appeared to be more important in the younger 
age group up to 54 years. 
The two samples (2002 and 2013) are compared in 
Table III with respect to the frequency of subclinical 
and clinically-relevant body dysmorphic concerns.
In order to present changes in the scale values in the 
DCQ, independent of an increased prevalence of BDD, 
the DCQ means of the study group excluding subjects 
in the subclinical and clinical group are presented in 
Table IV. The main effects for sex (higher value for 
women: F (1; 4,301) = 123.86; p < 0.001) and age (F 
(6; 4,301) = 5.80; p < 0.001) and the interaction effect 
sex × age (F (6; 4,301) = 2.33, p < 0.05) were significant. 
But the primary interest in this study is the change value. 
As in Table III, a more marked increase in value from 
2002 to 2013 is seen (F (1; 4,301) = 285.06; p < 0.001) and 
a significant interaction effect for sex × examination time 
(F (1; 4,301) =10.97; p < 0.001) which in content shows 
a greater increase in DCQ values in women than in men. 
The other interaction effects (age × examination time and 
age × sex × examination time) were not significant.
DISCUSSION
The assumption that the prevalence of dysmorphic con-
cerns increased in the years from 2002 to 2013 could 
be verified by this questionnaire study in which the 
Table III. Results of the study 2002 and 2013 of subclinical (≥ 11–< 14) and clinical (≥ 14) body dysmorphic disorder (BDD) with regard 
to gender, education, partnership and age
2002 2013 OR (95% CI) 
2013/2002Subclinical BDD Clinical BDD Subclinical BDD Clinical BDD
Total sample, n (%) 10 (0.5) 9 (0.5) 65 (2.6) 25 (1.0) χ2 (2)=32.71; 
p < 0.001
Subclinical: 5.16 (2.64; 10.06) 
Clinical: 2.20 (1.03; 4.73)
Women 7 (0.7) 8 (0.8) 37 (2.8) 16 (1.2) χ2 (2)=15.21; 
p < 0.001
Subclinical: 4.21 (1.87; 9.47) 
Clinical: 1.59 (0.68; 3.73)
Men 3 (0.3) 1 (0.1) 28 (2.4) 9 (0.8) χ2 (2)=19.35; 
p < 0.001
Subclinical: 7.38 (2.24; 24.35) 
Clinical: 7.11 (0.90:56.26)
OR (95% CI) women/men 2.06 (0.53; 7.99) 7.06 (0.88; 56.59) 1.18 (0.71; 1.93) 1.58 (0.70; 3.59)
University entrance diploma, n (%)
Without 5 (0.3) 8 (0.5) 56 (2.7) 21 (1.0) χ2 (2)=38.03; 
p < 0.001
Subclinical: 9.49 (3.79; 23.76) 
Clinical: 2.23 (0.98; 5.04)
With 5 (1.9) 1 (0.4) 8 (1.8) 4 (0.9) χ2 (2)= 0.60; 
ns
Subclinical: 0.91 (0.29; 2.81) 
Clinical: 2.27 (0.25; 20.43)
OR (95% CI) with/without 6.63 (1.91; 23.06 0.83 (0.10; 6.65) 0.63 (0.30; 1.34) 0.85 (0.29; 2.48)
Partner, n (%)
With 5 (0.5) 4 (0.4) 32 (2.5) 13 (1.0) χ2 (2)=18.42; 
p < 0.001
Subclinical: 5.38 (2.09; 13.86) 
Clinical: 2.73 (0.89; 8.41)
Without 5 (0.6) 5 (0.6) 33 (2.8) 12 (1.0) χ2 (2)=14.33; 
p < 0.001
Subclinical: 4.89 (1.90; 12.57) 
Clinical: 1.78 (0.62; 5.06)
OR (95% CI) without/with 1.26 (0.36; 4.36) 1.57 (0.42; 5.88) 1.14 (0.70; 1.87) 1.02 (0.47; 2.25)
Age, n (%)
< 24 years 0 (0.00) 2 (0.9) 11 (4.3) 2 (0.8)
25–34 years 4 (1.6) 0 (0.0) 19 (5.3) 3 (0.8)
35–44 years 3 (0.9) 0 (0.0) 11 (2.9) 3 (0.8)
45–54 years 3 (1.0) 0 (0.0) 14 (3.2) 5 (1.1)
55–64 years 3 (0.9) 1 (0.3) 7 (1.5) 1 (0.2)
65–74 years 1 (0.3) 0 (0.0) 9 (2.4) 1 (0.3)
> 75 years 2 (1.3) 0 (0.0) 3 (1.3) 1 (0.4)
Odds ratio (OR) were not calculated due to the small numbers of participants in the age-subgroups.
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data of two representative samples were compared. The 
point prevalence for subclinical or clinically-relevant 
BDD show an increase in dysmorphic concerns in the 
German population. The number of those affected sub-
clinically according to the DCQ (≥ 11–< 14) increased 
from 0.5% to 2.6 % in 2013. This means that the risk of 
developing at least a subclinical BDD was increased by 
about a factor 5 (OR = 5.16). Clinical BDD according 
to DCQ (≥ 14) increased from 0.5% in 2002 to 1.0%, 
corresponding to a doubling of the risk (OR = 2.2). 
In addition to the subclinical and clinical prevalence, 
the means of the subjects not assigned to these groups 
were compared. The means of these subjects have also 
more than doubled within the last about 10 years. Over-
all, thus, there is a marked increase in BDD symptoms at 
all examined levels. This corresponds to the hypothesis. 
The prevalence rates of clinical BDD found in similar 
representative studies range between 0.7–2.4% (33, 35). 
The method of diagnostics used differed considerably 
in the studies so that a direct comparison is hardly pos-
sible. Some studies only recorded a selected sample. 
Faravelli et al. (33), for example, recorded the preva-
lence by means of personal interviews done by general 
practitioners in the geographic area of Florence, which 
is probably not representative for all of Italy. Moreover, 
recordings by general practitioners does not necessarily 
represent specialist-specific knowledge of the diag-
nostics. Koran et al. (35) performed their prevalence 
study in a computer-assisted survey in only one city in 
the US, so that here, too, no representativeness for the 
USA is to be assumed. Brohede et al. (59) included only 
women in their study and found clinically-relevant BDD 
in 2.1% of the subjects, applying the Body Dysmorphic 
Disorder Questionnaire (BDDQ) in structured clinical 
interviews. When the symptoms of BDD according 
to DSM-4 (26) or DSM-5 (5) were examined, in a 
representative sample similar to the one in this study, 
the authors found prevalence of 1.7% (26), or 0.8%, 
respectively (5). Since the fluctuations in the prevalence 
figures did not show considerable difference and ranged 
from 0.7–2.4% (see Table I), the values obtained in our 
study appear to correspond to those of similar studies 
and the differences attributable simply to the various 
methodological approaches in the recording. 
Apart from total values, there were differences bet-
ween men and women. In women, subclinical BDD 
increased from 0.7% in 2002 to 2.8% in 2013, while the 
clinical form increased from 0.8% to 1.2% in women, 
the ORs for the subclinical form was 4.21, while it was 
1.59 for the clinical form. The ORs in the group of men 
were 7.38 for subclinical and 7.11 for clinical BDD. 
The prevalence increased for the subclinical group from 
0.3% to 2.4% and for the clinical form from 0.1% to 
0.8%. Only the increase (ORs) for the subclinical form 
was significant for both sexes. Apparently, more women 
than men with BDD are identified by the DCQ. On the 
other hand, men appear to have a greater increase in 
prevalence than women. With regard to the literature 
there is an equal frequency of BDD in women and men 
(27, 45, 60). In contradiction to this, in our study we 
found higher prevalence in women than in men in the 
samples of 2013 (2.8 % in women vs. 0.8 % in men). 
The differences between women and men are, however, 
not significant. Since the difference between women and 
men slightly decreased from 2002 to 2013, it must be 
assumed that men are increasingly affected. Contrary to 
this, the means of the DCQ increased more for women 
than for men, see Table IV. 
Contrary to the primary expectations, there was an 
increase in the representative sample of BDD preva-
lence in the group of persons without University En-
trance diploma. Persons without University Entrance 
diploma showed an increase in subclinical BDD from 
0.3% in 2002 to 2.7% in 2013 and regarding the clinical 
form from 0.5% in 2002 to 1.0% in 2013. This result 
corresponds to an OR of 9.49 in the subclinical group, 
which is significant. The extent to which social develop-
ments in ideal beauty among people without University 
Entrance diploma may be a possible explanation, can 
only be hypothetically discussed. 
The variable “Partnership” was also important when 
looking at the prevalence rates of BDD. A clear in-
crease of BDD symptoms occurred in the group “With 
partner”: Regarding the subclinical form there was an 
Table IV. Dysmorphic Concern Questionnaire  score in the total 
sample without subclinical and clinical cases, illustrated separately 
for men and women and age groups 
2002 (n = 1,915) 
Mean ± SD
2013 (n = 2,414) 
Mean ± SD
Total sample 0.99 ± 1.94 2.24 ± 2.54 
Women 1.24 ± 2.16 2.74 ± 2.65 
Men 0.72 ± 1.63 1.68 ± 2.28 
Age
< 24 years 1.20 ± 2.21 2.52 ± 2.80 
25–34 years 1.20 ± 2.10 2.56 ± 2.74 
35–44 years 1.19 ± 2.10 2.10 ± 2.42 
45–54 years 1.14 ± 2.17 2.36 ± 2.60 
55–64 years 0.77 ± 1.56 2.18 ± 2.39 
65–74 years 0.75 ± 1.68 2.05 ± 2.43 
> 75 years 0.66 ± 1.49 1.90 ± 2.39 
Age – Women
< 24 years 1.87 ± 2.69 3.07 ± 2.82 
25–34 years 1.49 ± 2.28 3.11 ± 2.80 
35–44 years 1.48 ± 2.29 2.82 ± 2.62 
45–54 years 1.47 ± 2.41 2.95 ± 2.73 
55–64 years 0.89 ± 1.75 2.62 ± 2.52 
65–74 years 0.84 ± 1.77 2.38 ± 2.46 
> 75 years 0.75 ± 1.62 2.19 ± 2.50 
Age – Men
< 24 years 0.66 ± 1.54 2.02 ± 2.69 
25–34 years 0.87 ± 1.81 1.82 ± 2.49 
35–44 years 0.84 ± 1.81 1.32 ± 1.90 
45–54 years 0.81 ± 1.83 1.69 ± 2.26 
55–64 years 0.64 ± 1.34 1.72 ± 2.17 
65–74 years 0.65 ± 1.57 1.69 ± 2.36 
> 75 years 0.32 ± 0.81 1.48 ± 2.16 
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increase from 0.5% in 2002 to 2.5% in 2013 (OR 5.38) 
and regarding the clinical form we observed an increase 
from 0.4% in 2002 to 1.0% in 2013 (OR 2.73), but in 
the group “Without partner”, the values regarding the 
subclinical form also increased from 0.6% in 2002 to 
2.8% in 2013 (OR 4.89), regarding the clinical form 
from 0.6% in 2002 to 1.0% in 2013 (OR 1.78). However, 
here again, only the increases regarding the subclinical 
form became significant.
Different changes in the individual age groups were 
not statistically calculated due to the low number of 
cases. Apparently, however, dysmorphic concerns are 
possible in all age groups.  
The DCQ means excluding subclinical and clinical 
subjects increased from 0.99 in 2002 to 2.24 in 2013. 
That means that dysmorphic concerns have apparently 
increased in the general population (see Table IV). 
One limitation of the representative survey might be 
the use of the screening questionnaire DCQ, since no 
personal interviews according to DSM-5 criteria could 
be performed. As already mentioned in the introduc-
tion, established questionnaires for recording BDD are 
the Dysmorphic Concern Questionnaire (DCQ; 57), 
the BDD Diagnostic Module (BDDDM) and the BDD 
Modification of the Yale-Brown Obsessive Compulsive 
Scale (BDD-YBOCS) (28, 30). The DCQ is easy to 
use with 7 questions and a cut-off value. The last two 
instruments are more detailed, semi-structured clinical 
interviews, which are not suitable for questionnaire 
studies. The FKS (31) is based on the criteria of the 
DSM-4 and must be re-validated according to the new 
classification in the DSM-5. 
Since there were several missing data in the DCQ 
(2002 median 132; 2013 median 4), data analyses refer 
to sample sizes of n = 1,934 for 2002 and n = 2,504 for 
2013. Due to the very different numbers of missing data 
in the two groups, a check was made whether the drop-
outs were selective in 2002: essential sociodemographic 
data from subjects with and without missing DCQ va-
lues were compared. There were no differences between 
the groups with respect to sex (χ2 (1) = 2.03, ns) and age 
(t (2,064) = 0.004, ns). Regarding the variable “Highest 
education level completed” (χ2 (1) = 4.61, p < 0.05), 
there were more with lower education and less with 
university entrance diploma or higher educational level 
in the groups with missing DCQ values. Regarding the 
variable “Partnership” (χ2 (1) = 6.11, p < 0.05 there were 
more subjects living with a partner than living alone in 
the group with missing DCQ values. The participants 
of the study mentioned their variables self-reported, 
there was no possibility for proofing their statements. 
The study was conducted as a point prevalence study. 
At both times (2002 and 2013), the BDD was recorded 
with identical standardized questionnaires. The aim was 
primarily to identify differences between the years 2002 
and 2013. One advantage of this comparison is that the 
same questionnaire was used twice at an interval of 11 
years and thus the changes are largely independent of 
the method. For reasons of practicability, it was not 
possible to perform a clinical interview according to 
the criteria of the DSM-5 in our study. To this extent 
it remains questionable whether BDD was actually 
present in those subjects who reported relevant dysmor-
phic concerns, or whether some objectively disfigured 
individuals were among the subjects. 
The increase in dysmorphic concerns in the German 
population apparently reflects a trend in the develop-
ment of the frequency of BDD. This should lead to 
paying more attention to the clinical picture of BDD. 
The DCQ proved valuable as a screening instrument 
in this study, since comparable prevalence rates were 
found in other studies using other instruments. A clini-
cal use appears sensible, since it can be assumed that 
prompt diagnostics and initiation of psychotherapy 
enables the doctor to secure greater effectiveness in 
relief of symptoms and of psychosocial consequences 
(24, 61, 62). The goal should therefore be to develop 
specific disorder-oriented therapeutic measures, which 
of course need to be examined in prospective therapy-
comparative studies. 
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